Teva Stock Is Jumping. Why Investors Are So Optimistic on the Drugmaker. -- Barrons.com

Dow Jones01-12

By Callum Keown

Teva Pharmaceutical Industries stock rose by 3% on Monday after the drugmaker issued upbeat guidance and targets for the years ahead.

The company said its full-year earnings per share will be at the higher end of its $2.55 to $2.65 range when it reports fourth-quarter results later in January. That's a relief more than anything else. Analysts are expecting EPS of $2.63.

Teva's 2026 guidance and targets for 2027 and beyond should give investors a bit more cause for optimism.

The company said it expects revenue in 2026 to be between flat and slightly down compared with last year, while forecasting low-single digit growth for 2027. Wall Street is currently predicting around a 0.5% fall in revenue in 2026 and a 2.5% jump the following year.

The company expects operating profit and adjusted Ebitda to grow versus last year and jump in 2027, with operating profit up 30% next year and rising more than 30% by 2030.

The company's American depositary receipts are up more than 60% over the past year.

Write to Callum Keown at callum.keown@dowjones.com

This content was created by Barron's, which is operated by Dow Jones & Co. Barron's is published independently from Dow Jones Newswires and The Wall Street Journal.

(END) Dow Jones Newswires

January 12, 2026 10:46 ET (15:46 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2602410435?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-12 23:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2602410435","market":"sh","top_or_hot":-1,"title":"Teva Stock Is Jumping. Why Investors Are So Optimistic on the Drugmaker. -- Barrons.com","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Callum Keown \n</p>\n<p>\n  <a href=\"https://laohu8.com/S/TEVA\">Teva</a> Pharmaceutical Industries stock rose by 3% on Monday after the drugmaker issued upbeat guidance and targets for the years ahead. \n</p>\n<p>\n  The company said its full-year earnings per share will be at the higher end of its $2.55 to $2.65 range when it reports fourth-quarter results later in January. That's a relief more than anything else. Analysts are expecting EPS of $2.63. \n</p>\n<p>\n  Teva's 2026 guidance and targets for 2027 and beyond should give investors a bit more cause for optimism. \n</p>\n<p>\n  The company said it expects revenue in 2026 to be between flat and slightly down compared with last year, while forecasting low-single digit growth for 2027. Wall Street is currently predicting around a 0.5% fall in revenue in 2026 and a 2.5% jump the following year. \n</p>\n<p>\n  The company expects operating profit and adjusted Ebitda to grow versus last year and jump in 2027, with operating profit up 30% next year and rising more than 30% by 2030. \n</p>\n<p>\n  The company's American depositary receipts are up more than 60% over the past year. \n</p>\n<p>\n  Write to Callum Keown at callum.keown@dowjones.com \n</p>\n<p>\n   This content was created by Barron's, which is operated by Dow Jones &amp; Co. Barron's is published independently from Dow Jones Newswires and The Wall Street Journal. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 12, 2026 10:46 ET (15:46 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Teva Stock Is Jumping. Why Investors Are So Optimistic on the Drugmaker. -- Barrons.com</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTeva Stock Is Jumping. Why Investors Are So Optimistic on the Drugmaker. -- Barrons.com\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-01-12 23:46</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Callum Keown \n</p>\n<p>\n  <a href=\"https://laohu8.com/S/TEVA\">Teva</a> Pharmaceutical Industries stock rose by 3% on Monday after the drugmaker issued upbeat guidance and targets for the years ahead. \n</p>\n<p>\n  The company said its full-year earnings per share will be at the higher end of its $2.55 to $2.65 range when it reports fourth-quarter results later in January. That's a relief more than anything else. Analysts are expecting EPS of $2.63. \n</p>\n<p>\n  Teva's 2026 guidance and targets for 2027 and beyond should give investors a bit more cause for optimism. \n</p>\n<p>\n  The company said it expects revenue in 2026 to be between flat and slightly down compared with last year, while forecasting low-single digit growth for 2027. Wall Street is currently predicting around a 0.5% fall in revenue in 2026 and a 2.5% jump the following year. \n</p>\n<p>\n  The company expects operating profit and adjusted Ebitda to grow versus last year and jump in 2027, with operating profit up 30% next year and rising more than 30% by 2030. \n</p>\n<p>\n  The company's American depositary receipts are up more than 60% over the past year. \n</p>\n<p>\n  Write to Callum Keown at callum.keown@dowjones.com \n</p>\n<p>\n   This content was created by Barron's, which is operated by Dow Jones &amp; Co. Barron's is published independently from Dow Jones Newswires and The Wall Street Journal. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 12, 2026 10:46 ET (15:46 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4557","symbol_name":"大麻股","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2602410435","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2602410435","pubTimestamp":1768232760,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Teva Pharmaceutical Industries stock rose by 3% on Monday after the drugmaker issued upbeat guidance and targets for the years ahead.The company said its full-year earnings per share will be at the higher end of its $2.55 to $2.65 range when it reports fourth-quarter results later in January. That's a relief more than anything else. Analysts are expecting EPS of $2.63.Teva's 2026 guidance and targets for 2027 and beyond should give investors a bit more cause for optimism.The company said it expects revenue in 2026 to be between flat and slightly down compared with last year, while forecasting low-single digit growth for 2027. Wall Street is currently predicting around a 0.5% fall in revenue in 2026 and a 2.5% jump the following year.The company expects operating profit and adjusted Ebitda to grow versus last year and jump in 2027, with operating profit up 30% next year and rising more than 30% by 2030.The company's American depositary receipts are up more than 60% over the past year.Th","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4557":"大麻股","LU1983299246.USD":"SCHRODER ISF HEALTHCARE INNOVATION \"A\" (USD) ACC","TEVA":"梯瓦制药","ISBC":"投资者银行","BK4596":"哈里斯概念","BK4007":"制药","BK4559":"巴菲特持仓","BK4584":"避孕概念","BK4566":"资本集团","BK4211":"区域性银行","BK4588":"碎股","BK4585":"ETF&股票定投概念"},"translate_title":"梯瓦股价正在上涨。为什么投资者对这家制药商如此乐观。——Barrons.com","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TEVA":0.9,"ISBC":1.5},"content_text":"By Callum Keown \n\n\nTeva Pharmaceutical Industries stock rose by 3% on Monday after the drugmaker issued upbeat guidance and targets for the years ahead. \n\n\n  The company said its full-year earnings per share will be at the higher end of its $2.55 to $2.65 range when it reports fourth-quarter results later in January. That's a relief more than anything else. Analysts are expecting EPS of $2.63. \n\n\n  Teva's 2026 guidance and targets for 2027 and beyond should give investors a bit more cause for optimism. \n\n\n  The company said it expects revenue in 2026 to be between flat and slightly down compared with last year, while forecasting low-single digit growth for 2027. Wall Street is currently predicting around a 0.5% fall in revenue in 2026 and a 2.5% jump the following year. \n\n\n  The company expects operating profit and adjusted Ebitda to grow versus last year and jump in 2027, with operating profit up 30% next year and rising more than 30% by 2030. \n\n\n  The company's American depositary receipts are up more than 60% over the past year. \n\n\n  Write to Callum Keown at callum.keown@dowjones.com \n\n\n   This content was created by Barron's, which is operated by Dow Jones & Co. Barron's is published independently from Dow Jones Newswires and The Wall Street Journal. \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 12, 2026 10:46 ET (15:46 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2602410435","isCrawlerRequest":true}